舒血宁治疗脑衰弱综合征的双盲对照研究  

A Double-Blind Contrast of GinkgoBiloba EGb761 for the Treatment of ChronicSchizophrenia

作　　者：李世泽[1] 赵安全[1] 于江[1] 李福海[1] 沈振明[1] 胡振宏 李广田 高丽英 王醒华 胡仁南 王德富 王洪灏 

机构地区：[1]河北省唐山市精神康复医院,唐山市卫校附瞩医院,唐山市钢铁公司医院,哲里木盟精神病院

出　　处：《中国民康医学》1996年第5期279-281,共3页Medical Journal of Chinese People’s Health

摘　　要：１４３例脑衰弱综合征患者随机分成舒血宁组和对照组，进行双盲的前瞻性研究。通过脑衰弱量表，打洞试验，连线实验的回查，结果表明：应用舒血宁治疗脑衰弱综合征，整体疗效明显优于对照组，脑衰弱量表的总评分显著优于对照组，而且对脑衰弱量表各个症状都有显著改善，易激惹，烦恼两项症状降分幅度较大，打洞、连线试验表明舒血宁治疗后患者的注意力、记忆力都有明显的改善，而且没有发现明显副作用。作者认为舒血宁治疗脑衰弱综合征有显著的作用，作为一种治疗脑血管疾患伴发精神症状和早期预防脑血管痴呆的新药是可行的。t reported the double-blind contrast study ofEGb761 treating 40 chronic schizophrenics , amongwhich 20 in the EGb761 group and 20 in the controlgroup. The clinical curative effects and side effectswere assessed by BPRS, SANS and TESS. Thechanges in the state of the illness appeared in the2nd, 4th, 6th, sth, 12th, 14th, 16th weeks afterthe treatment by dynamic observation. The resultsshowed that EGb761 was better than placebo in de-veloping the negative symptoms of chronicschizophrenia and improvingthe curative effects ofanti - psychotics.

关 键 词：银杏叶提取物 舒血宁 脑衰弱综合征 

分 类 号：R972.6[医药卫生—药品]